480449-71-6

Edoxaban tosylate (Lixiana; Daiichi Sankyo, Tokyo, Japan), known as DU-176b in clinical trials, is a novel oral direct factor Xa inhibitor. Edoxaban has good bioavailability with maximum plasma concentration achieved 1–2 h after ingestion and plasma half-life of 8–10 h. Edoxaban is a novel anticoagulant (NOAC) indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis and pulmonary embolism.

ChEBI: An organosulfonate salt obtained by combining equimolar amounts of edoxaban and 4-toluenesulfonic acid. Used (in the form of its monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.